In the ASCERTAIN-V trial, treatment with decitabine/cedazuridine plus venetoclax yielded a complete remission (CR) rate of 41.6% and a CR/CRh rate of 52.5% in patients ineligible for intensive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results